Cytokinetics Highlights Phase 3 Aficamten Data at ESC
SOUTH SAN FRANCISCO, Calif., Aug. 29, 2026 Cytokinetics, Incorporated announced additional clinical data for aficamten from the ACACIA-HCM and...
Bristol Myers Squibb
Advertisement
Bristol Myers Squibb Reports Five-Year Camzyos Data
PRINCETON, N.J., August 26, 2026 Bristol Myers Squibb presented new long-term data for Camzyos® (mavacamten) at the European Society...
Leads Biolabs Advances Opamtistomig Toward Approval
NANJING, China, August 21, 2026 Nanjing Leads Biolabs Co., Ltd. announced that China’s Center for Drug Evaluation (CDE) under...
Chai Discovery and BMS Advance AI Antibody Discovery
San Francisco, California, August 20, 2026 Chai Discovery has announced a collaboration with Bristol Myers Squibb (BMS) to advance...
Bristol Myers Squibb Expands AI Collaboration with NVIDIA
PRINCETON, N.J., July 20, 2026 Bristol Myers Squibb (BMS) announced a major expansion of its strategic collaboration with NVIDIA...
Advertisements
Tempus AI and Bristol Myers Squibb Expand AI Clinical Trial Partnership
CHICAGO, Illinois, May 2026 Tempus AI announced an expanded strategic collaboration with Bristol Myers Squibb aimed at improving the...
Tigerlily Foundation and BMS Expand Clinical Trial Access
Washington, D.C. – May 15, 2026 Tigerlily Foundation announced a new collaboration with Bristol Myers Squibb focused on improving...
BMS and Hengrui Form $15 Billion Drug Development Alliance
SHANGHAI, China and PRINCETON, N.J., May 12, 2026 Hengrui Pharma and Bristol Myers Squibb (BMS) have announced a landmark...
Bristol Myers Squibb Secures EU Approval for Sotyktu in Psoriatic Arthritis
PRINCETON, N.J., May 11, 2026 Bristol Myers Squibb announced that the European Commission has approved Sotyktu (deucravacitinib) for the...
Atrium Therapeutics Earns $15M Milestone from Bristol Myers Squibb
San Diego, California, USA – April 23, 2026 Atrium Therapeutics announced it has achieved a $15 million development milestone...
Advertisement
